Protective mechanisms of a microbial oil against hypercholesterolemia: evidence from a zebrafish model
- PMID: 37435570
- PMCID: PMC10332275
- DOI: 10.3389/fnut.2023.1161119
Protective mechanisms of a microbial oil against hypercholesterolemia: evidence from a zebrafish model
Abstract
A Western diet elevates the circulating lipoprotein and triglyceride levels which are the major risk factors in cardiovascular disease (CVD) development. Consumption of long-chain omega-3 fatty acids can stall the disease progression. Although these fatty acids can significantly impact the intestine under a hypercholesterolemic condition, the associated changes have not been studied in detail. Therefore, we investigated the alterations in the intestinal transcriptome along with the deviations in the plasma lipids and liver histomorphology of zebrafish offered DHA- and EPA-rich oil. Fish were allocated to 4 dietary treatments: a control group, a high cholesterol group and microbial oil groups with low (3.3%) and high (6.6%) inclusion levels. We quantified the total cholesterol, lipoprotein and triglyceride levels in the plasma. In addition, we assessed the liver histology, intestinal transcriptome and plasma lipidomic profiles of the study groups. The results suggested that higher levels of dietary microbial oil could control the CVD risk factor indices in zebrafish plasma. Furthermore, microbial oil-fed fish had fewer liver vacuoles and higher mRNA levels of genes involved in β-oxidation and HDL maturation. Analyses of the intestine transcriptome revealed that microbial oil supplementation could influence the expression of genes altered by a hypercholesterolemic diet. The plasma lipidomic profiles revealed that the higher level of microbial oil tested could elevate the long-chain poly-unsaturated fatty acid content of triglyceride species and lower the concentration of several lysophosphatidylcholine and diacylglycerol molecules. Our study provides insights into the effectiveness of microbial oil against dyslipidemia in zebrafish.
Keywords: DHA; EPA; RNA seq; bioactive compounds; cardiovascular disease; plasma lipidomics.
Copyright © 2023 Gora, Rehman, Dias, Fernandes, Olsvik, Sørensen and Kiron.
Conflict of interest statement
JD was employed by SPAROS Lda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor SM declared a past collaboration with the author VK.
Figures
References
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
